Mikhail Blagosklonny, the cancer and old age problem solver

Mikhail Blagosklonny is a famous scientist who has put his life’s work in the study of cancer and aging. Blagosklonny’s interests include the research on cancer and the cancer therapies which protect the body’s cells against damage, as well as the chemistry behind aging and anti-aging medications. He has come up with a hypothesis on the possibility on the target of rapamycin, TOR that signals aging and cancer. Blagosklonny proposed the use of rapamycin, a widely used drug, as a probable treatment for life extension.Mikhail Blagosklonny was a former student of the First Pavlov State Medical University of Saint Petersburg studying his Master’s Degree in internal medicine and Ph.D. in the study of experimental medicine and cardiology. Blagosklonny’s previous careers before fully devoting himself to being a scientist include associate medicine professor at the New York Medical College, Valhalla, New York and senior scientist position at the Ordway Research Institute in Albany, New York.

Blagosklonny believes that it is a misguided perception for someone to think that aging cannot be solved scientifically. This is because as per the TOR model, you can be able to prevent diseases and treat aging by using rapamycin and other rapalogs if you consume them in proper doses. Due to this, it is no longer assumed that aging is brought about by the accumulation of damaged molecules in the body. Rapamycin does this by improving the immunity as humans’ age. Rapamycin was launched in 2016, it has been used in the treatment of cancer, autoimmunity, cardiovascular diseases, and metabolic disorders. Rapamycin may also be administered to patients suffering from osteoporosis aging and Alzheimer. When rapamycin is used as an aging drug, it slows down the senescence which also brings about prevention of diseases.

Rapamycin is a drug that can even be used daily and for several years with patients that have undergone body transplants. The drug is very safe, in that, scientists used it on healthy individuals. It works by transforming one’s immunity from that of an aged person to that of an infant’s. Preclinical tests revealed that the drug did not have any anti-tumor, calorie restriction, and bone-sparing side effects.Blagosklonny admits that it may not be possible to get rid of death and have people living forever. This is because the ability to age in human beings is quasi-programmed and not accidental. Having to inhibit the TOR may be able to extend the life span of a person, which in turn reveals the post-aging syndrome.In his quest to treat cancer, Mikhail Blagosklonny tries managing how to come up with new ways to provide cancer treatment that is both inexpensive and painless. He hopes that he will be able to find a way to eliminate the cancer cells from the human body without having to destroy other healthy cells which have a crucial job in the rejuvenation of the body and the mind. Blagosklonny hopes that his work on cancer will inspire other scientists to pick up from where he will stop, to ensure the treatment of cancer is affordable to all those who suffer from it.

Eric Lefkofsky: American Businessman

Entrepreneur and Detroit, Michigan native Eric Paul Lefkofsky is presently the CEO (chief executive officer) and co-founder of Tempus. He is also the chairman and co-founder of Groupon, the co-founder of Mediaocean, Echo Global Logistics, Uptake, InnerWorkings and the co-founder of Lightbank.

Lefkofsky’s Education

Lefkofsky graduated from Southfield-Lathrup High School in 1987. He went to the University of Michigan and graduated from there in 1991. He earned his Juris Doctor from the University of Michigan Law School in 1993. Learn more.

Working Ventures

Later that year he took a job selling carpet. he and his school friend, Brad Keywell, secured a loan and bought a clothing company in Madison, Wisconsin named Brandon Apparel. In 1999 the partners launched an online venture they called Starbelly.They specialized in promotional products and sold the business to Halo Industries the next year. By the fall of 2001, Lefkofsky had also co-launched an enterprise now known as InnerWorkings. He would take a seat on the board of directors in 2006 and remain there until 2012.He partnered with Keywell to create the freight logistics company Echo Global Logistics in 2005. By the summer of 2006, they were launching yet another enterprise christened MediaBank. Lefkofsky threw in $1 million dollars to co-create ThePoint.com with Andrew Mason in 2008. In late 2009, they relabeled the business Groupon.com.

Partners Keywell and Lefkofsky and Keywell set up still another new venture in 2010. It was called Lightbank. The purpose of this particular effort focused on developing other new businesses in the vicinity of Chicago, Illinois.Prior to the end of 2011, the internet industry has grown to become the most successful online enterprise since Google. The $700 million profit made the shares worth $20 a piece. In 2012 the United States Department of Justice OKed a merger of the corporation with Donovan Data Systems. The newly-formed collaborative effort was named Mediaocean. Lefkofsky co-launched Uptake, LLC, an analytics business, in 2014.Finally, Lefkofsky co-launched Tempus in 2016. Tempus is a tech-based business that helps physicians give cancer patients more personalized care. As this goes to press, he is still the company’s CEO.

Clay Siegall’s Lifelong Quest For Cancer Cure


Clay Siegall seems like the kind of guy that’s pretty interested in science. He has been all his life. He believes in the pursuit of scientific truth at all costs, whether it is concerning climate change, the science of the universe or the pursuit for a cancer cure.

His love of science is reflected in his blog. You can also see the guy really loves NFL football. His blog is full of NPR retweets concerning all sorts of science. Upon first glance, you can see that he is incredibly concerned about the environment. On March 14, 2017, he posted a story about environmental science, climate and the forecast of half the world’s Arctic sea ice. It is hard to say what his political leanings are, but it is clear that the scientific stories that he posts on his website are in contradiction to everything the Trump administration has stated about science.

Another glimpse into his beliefs is the reposting of an NPR story about how couples can navigate the Trump administration’s repeal and replacement of the Affordable Care Act. As the CEO of Seattle Genetics, you can see that he is very concerned with people losing their health care. After all, he has spent a lifetime pursuing scientific treatments and cures for cancer.

He spent the better part of the 1980s and 1990s as a cancer researcher for a variety of scientific groups. It is here that he discovered that each cancer is uniquely individual and cannot be broadly categorized. This inspired him to cofound Seattle Genetics in order to target cancer treatment more precisely. Now, Seattle Genetics is coming out with such groundbreaking cancer treatments that the private organization is often forced to wait for the government to approve of its medications. It’s moving much faster than the speed of government.

As the CEO of Seattle Genetics, Clay Siegall has moved more into the role of business administration within the cancer treatment community. He was able to raise $1.2 billion for his company since it went public in 2001. He is also now totally engrossed with every aspect of the business from research to distribution.